Weight loss medications have been in the spotlight lately, and for good reason — they’re changing lives. But with all the buzz around names like Mounjaro and Wegovy (AKA - Ozempic), it’s easy to get confused. Are they the same thing? Are they safe? And how on earth do you choose?
Let’s break it down — science, hormones, studies and all — so you can make an informed choice that works for your body, not against it.
GLP-1 stands for glucagon-like peptide-1 — a mouthful, we know, but stay with us. It’s a hormone your body naturally produces in your gut in response to food. GLP-1 has three key jobs:
It slows down how fast your stomach empties, so you feel fuller for longer.
It signals to your brain that you’re satisfied.
It helps your pancreas release insulin, which regulates blood sugar.
GLP-1 medications mimic this hormone to support appetite regulation, reduce cravings, and improve blood sugar control — all without the intense mental effort of constant willpower.
So no, it’s not “just a willpower issue.” These medications work on your biology, not your character.
If GLP-1 is the lead singer, glucagon and GIP (glucose-dependent insulinotropic polypeptide) are the backing vocalists that make the whole performance stronger.
Glucagon raises blood sugar levels when needed and promotes fat burning.
GIP helps the pancreas release insulin and may reduce appetite, but also helps the body store fat — which is why combining it with GLP-1 is game-changing.
This is where Mounjaro enters the chat.
Both are weekly injectable medications, but the hormones they target set them apart:
Wegovy (semaglutide) is a GLP-1 receptor agonist. It mimics the GLP-1 hormone.
Mounjaro (tirzepatide) is a dual agonist, mimicking both GLP-1 and GIP — sometimes referred to as a "twincretin".
What does that mean for your body?
With Wegovy, you get appetite suppression, slower digestion, and better blood sugar control.
With Mounjaro, you also get enhanced fat-burning and insulin regulation thanks to the GIP effect.
It’s not about which one is “better” — it’s about how your body responds.
Let’s talk evidence — because we know you want more than just marketing hype.
In clinical trials, Wegovy helped participants lose an average of 15% of their body weight over 68 weeks when paired with diet and lifestyle changes.
Source: NEJM, 2021, Wilding et al.
Mounjaro? In a similar timeframe, participants lost up to approximately 20% of their body weight.
Source: NEJM, 2022, Jastreboff et al.
Mounjaro and Wegovy are approved specifically for weight management in people with a BMI ≥30 (or ≥27 with weight-related conditions).
Let’s not pretend this is a one-size-fits-all decision. Here are a few things to consider:
✅ Are you insulin resistant or prediabetic? Both medications can help, but Mounjaro’s GIP effect may give it an edge.
✅ Do you have PCOS, hormonal imbalances or intense carb cravings? Either may help, but you might respond differently — your provider can help you test and adjust.
✅ Have you tried GLP-1s before and hit a plateau? You may benefit from the dual action of Mounjaro.
✅ Watching your budget? Mounjaro’s recent UK price hike (coming into force 1 September) — up to 170% for higher doses — means future costs may significantly increase compared to Wegovy.
Ultimately, it's about your goals, your history, and your body’s unique needs. That’s why clinical oversight and proper consultation matter.
We’re not here to sell you a dream. We’re here to back you up with:
Expert consultations with female-led clinicians who understand the mental and hormonal load.
Safe prescriptions with support every step of the way — including choosing between Wegovy and Mounjaro.
Ongoing check-ins, supplement guidance, and reorder options that don’t make you jump through hoops.
And if you’re still unsure? That’s okay. Your body, your timeline.